Evidence map›Paper›PMID 41345856›Full record

ArticleAnnals of clinical and translational neurology2026

Refractory Status Epilepticus Treated With Bilateral Pulvinar Deep Brain Stimulation-A Case Study.

Mengxuan Tang, Amerta Bai, Felipe Rodridgues Marques Ferreira, Sandipan Pati, Thaddeus Walczak, Benjamin Miller, Oladi Bentho, Thomas Henry, Ilo Leppik, Minoo Shams and 7 more

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Annals of clinical and translational neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Mengxuan TangDepartment of Neurology, University of Minnesota Medical Center, Minneapolis, Minnesota, USA.
Amerta BaiDepartment of Neurology, University of Minnesota Medical Center, Minneapolis, Minnesota, USA.ORCID 0009-0006-9087-3906
Felipe Rodridgues Marques FerreiraDepartment of Neurology, University of Minnesota Medical Center, Minneapolis, Minnesota, USA.
Sandipan PatiDepartment of Neurology, University of Minnesota Medical Center, Minneapolis, Minnesota, USA.
Thaddeus WalczakDepartment of Neurology, University of Minnesota Medical Center, Minneapolis, Minnesota, USA.
Benjamin MillerDepartment of Neurology, University of Minnesota Medical Center, Minneapolis, Minnesota, USA.
Oladi BenthoDepartment of Neurology, University of Minnesota Medical Center, Minneapolis, Minnesota, USA.
Thomas HenryDepartment of Neurology, University of Minnesota Medical Center, Minneapolis, Minnesota, USA.
Ilo LeppikDepartment of Neurology, University of Minnesota Medical Center, Minneapolis, Minnesota, USA.
Minoo ShamsDepartment of Neurology, University of Minnesota Medical Center, Minneapolis, Minnesota, USA.
Zhiyi ShaDepartment of Neurology, University of Minnesota Medical Center, Minneapolis, Minnesota, USA.
Zachary SangerDepartment of Biomedical Engineering, University of Minnesota, Minneapolis, Minnesota, USA.
Theoden I NetoffDepartment of Biomedical Engineering, University of Minnesota, Minneapolis, Minnesota, USA.
Thomas LiskoDepartment of Neurosurgery, University of Minnesota Medical Center, Minneapolis, Minnesota, USA.
Anant NaikDepartment of Neurosurgery, University of Minnesota Medical Center, Minneapolis, Minnesota, USA.
Robert McGovernDepartment of Neurosurgery, University of Minnesota Medical Center, Minneapolis, Minnesota, USA.
Sima PatelDepartment of Neurology, University of Minnesota Medical Center, Minneapolis, Minnesota, USA.ORCID 0000-0002-3788-3439

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

New-onset refractory status epilepticus (NORSE) arises without an identifiable cause or prior epilepsy history, with a 16%-27% mortality rate and significant long-term neurological sequelae. Neuromodulation such as deep brain stimulation (DBS) targeting the anterior and centromedian thalamic nuclei has shown promise when the traditional approach of anti-seizure medications (ASMs), anesthetics, and immunomodulation fails. We present a case of cryptogenic NORSE in a 30-year-old male with autism and developmental delay, with refractory seizures localized to bilateral posterior quadrants. Sensing-enabled DBS targeting the pulvinar thalami led to decreased seizure burden and clinical improvement, highlighting the importance of tailoring neuromodulatory targets to seizure localization.

Indexed as

Deep Brain StimulationDrug Resistant EpilepsyPulvinarStatus EpilepticusAdultHumansMaledeep brain stimulationepilepsystatus epilepticusthalamic neuromodulatory targets

Identifiers

PMID41345856
PMCPMC12968458

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.